NCT05282823已完成不适用
POLARx™ Cardiac Cryoablation System Post Market Clinical Study POLAR SMART
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 295
- 试验地点
- 19
- 主要终点
- Failure Free Rate
研究概览
简要总结
This is a post-market study collecting real-world clinical data on safety, effectiveness and procedural success of Boston Scientific Cardiac Cryoablation System (POLARx™ System)
详细描述
The study will collect real-world clinical data on safety, effectiveness and procedural success of Boston Scientific Cardiac Cryoablation System (POLARx™ System) when used to perform pulmonary vein isolation (PVI) in the ablation treatment of De Novo Atrial Fibrillation (AF).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects indicated for the treatment of AF with the cryoablation system;
- •Subjects who are willing and capable of providing informed consent;
- •Subjects who are willing and capable of participating in all testing associated with this clinical study at an approved clinical investigational center;
- •Subjects who are of legal age to give informed consent specific to the national law.
排除标准
- •Any known contraindication to an AF ablation or anticoagulation, including those listed in the IFU/Tenpubunsyo as legally approved conditions;
- •Any prior LA ablation;
- •AF secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause;
- •Known or pre-existing severe Pulmonary Vein Stenosis;
- •Evidence of cardiac myxoma, LA thrombus or intracardiac mural thrombus;
- •Previous cardiac surgery (e.g. ventriculotomy or atriotomy, CABG, PTCA, PCI, ventricular fistula or atrial incision) and any surgery within 90 days prior to enrollment;
- •Any implanted cardiac device (e.g. PM, ICD, CRT, valve replacement, LAAO, etc) within 90 days prior to enrollment;
- •Any planned OR scheduled cardiac device procedure (e.g. PM, ICD, CRT, valve replacement, LAAO, etc) during and post PVI ablation (during and post-index procedure);
- •Any planned ablation in LA except PVI procedure and roof line ablation;
- •Any planned ablation in ventricles;
- •Subjects undergoing atrial septal defect patch or other surgical procedures at or near the atrial septal defect;
- •Subjects with severe valvular disease OR with a prosthetic - mechanical or biological - heart valve (not including valve repair and annular rings);
- •Presence of any pulmonary vein stents;
- •Subjects with active systemic infection;
- •Subjects that have vena cava embolic protection filter devices and/or known femoral thrombus;
- •Any previous history of cryoglobulinemia;
- •Subjects that are unable to undergo atrium access safely or operate in the atrium as per investigator's medical judgement;
- •Subjects with no vascular access or obstruction of the femoral vein;
- •Subjects with blood coagulation disorders or diseases;
- •Any prior history of documented cerebral infarct, TIA or systemic embolism (excluding a post-operative deep vein thrombosis (DVT)) ≤ 180 days prior to enrollment;
- •Subjects who are hemodynamically unstable;
- •The subject is unable or not willing to complete follow-up visits and examination for the duration of the study;
- •Subjects with life expectancy ≤ 1 year per investigator's medical judgement;
- •Women of childbearing potential who are, or plan to become, pregnant during the time of the study (assessment per investigator's discretion);
- •Subjects with unrecovered/unresolved Adverse Events from any previous invasive procedure;
- •Subjects who are currently enrolled in another investigational study or registry that would directly interfere with POLAR SMART study. Exception when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor for approval.
结局指标
主要结局
Failure Free Rate
时间窗: 12 months
Failure to achieve acute procedural success during the procedure, or any documented recurrent AF episode(s), or new onset of atrial flutter (AFL) or any other atrial tachycardia (AT) events between Days 91 and 12-Month, or any interventions for AF/AFL/AT between Days 91 and 12-Month
Safety Event Free Rate
时间窗: 12 months
Freedom from procedure and device-related adverse events post-index procedure
次要结局
- Failure Free Rate(6 month)
研究者
研究点 (19)
Loading locations...
相似试验
已完成
不适用
POLARx Cardiac Cryoablation System StudyAtrial FibrillationNCT04250714Boston Scientific Corporation400
已完成
不适用
POLARx Cardiac Cryoablation System Post Market Clinical Follow-up studyAtrial Fibrilation10007521NL-OMON54978Boston Scientific120
终止
不适用
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) StudyAtrial FibrillationPersistent Atrial FibrillationParoxysmal Atrial FibrillationAtrial FlutterNCT05416086Adagio Medical91
已完成
不适用
Cryoablation System FIM/CE Mark StudyAtrial FibrillationNCT03723070Boston Scientific Corporation88
进行中（未招募）
不适用
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable AnginaCoronary SyndromeCryotherapy EffectMyocardial DiseaseAtherosclerosis, CoronaryMyocardial InfarctionCoronary Artery DiseaseNCT05600088Cryotherapeutics SA30